全文获取类型
收费全文 | 1355篇 |
免费 | 100篇 |
国内免费 | 19篇 |
专业分类
儿科学 | 194篇 |
妇产科学 | 32篇 |
基础医学 | 102篇 |
口腔科学 | 2篇 |
临床医学 | 181篇 |
内科学 | 409篇 |
皮肤病学 | 2篇 |
神经病学 | 86篇 |
特种医学 | 8篇 |
外科学 | 89篇 |
综合类 | 110篇 |
预防医学 | 86篇 |
眼科学 | 5篇 |
药学 | 132篇 |
2篇 | |
中国医学 | 28篇 |
肿瘤学 | 6篇 |
出版年
2024年 | 5篇 |
2023年 | 18篇 |
2022年 | 64篇 |
2021年 | 80篇 |
2020年 | 49篇 |
2019年 | 43篇 |
2018年 | 46篇 |
2017年 | 66篇 |
2016年 | 56篇 |
2015年 | 72篇 |
2014年 | 87篇 |
2013年 | 119篇 |
2012年 | 64篇 |
2011年 | 70篇 |
2010年 | 61篇 |
2009年 | 73篇 |
2008年 | 46篇 |
2007年 | 57篇 |
2006年 | 34篇 |
2005年 | 30篇 |
2004年 | 33篇 |
2003年 | 23篇 |
2002年 | 21篇 |
2001年 | 13篇 |
2000年 | 11篇 |
1999年 | 21篇 |
1998年 | 16篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1995年 | 10篇 |
1994年 | 7篇 |
1993年 | 7篇 |
1992年 | 10篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 10篇 |
1988年 | 10篇 |
1987年 | 8篇 |
1986年 | 10篇 |
1985年 | 11篇 |
1984年 | 11篇 |
1983年 | 9篇 |
1982年 | 10篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1979年 | 9篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1974年 | 4篇 |
1972年 | 5篇 |
排序方式: 共有1474条查询结果,搜索用时 15 毫秒
31.
32.
Erdem Durmaz Sarah E. Flanagan Mesut Parlak Sian Ellard Sema Akcurin ?ffet Bircan 《Journal of clinical research in pediatric endocrinology》2014,6(2):119-121
Hyperinsulinemic hypoglycemia (HH) is the commonest cause of persistent hypoglycemia in the neonatal and infancy periods. Mutations in the ABCC8 and KCNJ11 genes, which encode subunits of the ATP-sensitive potassium channel in the pancreatic beta cell, are identified in approximately 50% of these patients. The first-line drug in the treatment of HH is diazoxide. Octreotide and glucagon can be used in patients who show no response to diazoxide. Nifedipine, a calcium-channel blocker, has been shown to be an effective treatment in a small number of patients with diazoxide-unresponsive HH. We report a HH patient with a homozygous ABCC8 mutation (p.W1339X) who underwent a near-total pancreatectomy at 2 months of age due to a lack of response to diazoxide and octreotide treatment. Severe hypoglycemic attacks continued following surgery, while the patient was being treated with octreotide. These attacks resolved when nifedipine was introduced. Whilst our patient responded well to nifedipine, the dosage could not be increased to 0.75 mg/kg/day due to development of hypotension, a reported side effect of this drug. Currently, our patient, now aged 4 years, is receiving a combination of nifedipine and octreotide treatment. He is under good control and shows no side effects. In conclusion, nifedipine treatment can be started in patients with HH who show a poor response to diazoxide and octreotide treatment. 相似文献
33.
Joseph P. Shivers Linda Mackowiak Henry Anhalt Howard Zisser 《Journal of diabetes science and technology》2013,7(3):789-794
Safe and widespread use of diabetes technology is constrained by alarm fatigue: when someone receives so many alarms that he or she becomes less likely to respond appropriately. Alarm fatigue and related usability issues deserve consideration at every stage of alarm system design, especially as new technologies expand the potential number and complexity of alarms. The guiding principle should be patient wellbeing, while taking into consideration the regulatory and liability issues that sometimes contribute to building excessive alarms. With examples from diabetes devices, we illustrate two complementary frameworks for alarm design: a “patient safety first” perspective and a focus on human factors. We also describe opportunities and challenges that will come with new technologies such as remote monitoring, adaptive alarms, and ever-closer integration of glucose sensing with insulin delivery. 相似文献
34.
《Expert opinion on biological therapy》2013,13(5):539-564
Background: Dendritic cells (DCs) play a major role in cell-mediated immunotherapy. In this approach, DCs are isolated from cancer patients and pulsed with exogenous and specific tumor antigens in vitro, and the antigen-loaded DCs are then transferred to the hosts to enhance the immune response against tumor targets. Clinical observations and animal studies have shown that tumors can elicit immune responses caused by tumor infiltration of T-lymphocytes. Several pilot clinical trials have been recently conducted using this strategy for treating several types of cancers. Objective: To optimize DC-based therapy with emerging molecular imaging techniques. Methods: A review of the most current literature on DCs and imaging work. Results/conclusion: The translational application of DC-based therapy can be supported greatly through molecular imaging. New discoveries on DC migration and behavior in vivo will lead to new advances in the treatment of a broad range of cancers. 相似文献
35.
《Journal of the American Medical Directors Association》2021,22(9):1889-1897.e5
ObjectiveTo investigate the prevalence, outcomes, and factors associated with potential glycemic overtreatment and undertreatment of type 2 diabetes mellitus (T2DM) in long-term care facilities (LTCFs).DesignSystematic review.Setting and ParticipantsResidents with T2DM and aged ≥60 years living in LTCFs.MeasuresArticles published between January 2000 and September 2020 were retrieved following a systematic search of MEDLINE, EMBASE, Cochrane Library, CINAHL plus, and gray literature. Inclusion criteria were the reporting of (1) potential overtreatment and undertreatment quantitatively defined (implicitly or explicitly) based on hemoglobin A1c (HbA1c) and/or blood glucose; (2) prevalence, outcomes, and associated factors of potential glycemic overtreatment and undertreatment; and (3) the study involved residents of LTCFs.ResultsFifteen studies were included. Prevalence of potential overtreatment (5%–86%, n = 15 studies) and undertreatment (1.4%–35%, n = 8 studies) varied widely among facilities and geographical locations, and according to definitions used. Prevalence of potential overtreatment was 16%–74% when defined as treatment with a glucose-lowering medication in a resident with ≥1 hypoglycemia risk factor or serious comorbidity, together with a HbA1c <7% (n = 10 studies). Potential undertreatment was commonly defined as residents on glucose-lowering medication having HbA1c >8.5% and the prevalence 1.4%–14.8% (n = 6 studies). No studies prospectively measured resident health outcomes from overtreatment and undertreatment. Potential overtreatment was positively associated with use of oral glucose-lowering medications, dementia diagnosis or dementia severity, and/or need for assistance with activities of daily living (n = 2 studies). Negative association was found between potential overtreatment and use of insulin/combined insulin and oral glucose-lowering medication. No studies reported factors associated with potential undertreatment.Conclusions and ImplicationsThe prevalence of potential glycemic overtreatment and undertreatment varied widely among residents with T2DM depending on the definition(s) used in each study. Longitudinal studies examining associations between glycemic management and health outcomes, and the use of consensus definitions of overtreatment and undertreatment are required to establish findings about actual glycemic overtreatment and undertreatment in LTCFs. 相似文献
36.
原发性肝癌病人出现低血糖反应者并不少见,但常被临床医生忽视。我院自2011年2月至2012年1月期间的共收治原发性肝癌伴发低血糖病人15例。现报告如下。1临床资料本组原发性肝癌伴发低血糖病人15例。男13例,女2例;年龄48~62岁, 相似文献
37.
《Scandinavian journal of gastroenterology》2013,48(9):892-896
Background: After nutrient ingestion there is an early response of glucagon-like peptide 1 (GLP-1) immunoreactivity, although GLP-1 is mainly produced in endocrine cells from the lower gut (ileum and colon/rectum), suggesting that indirect stimulation is important after the ingestion of carbohydrates that are predominantly absorbed from the upper intestine.Methods: To enable contact of sucrose with lower gut mucosa, sucrose was administered by mouth with and without the simultaneous ingestion of 100mg of the α-glucosidase inhibitor acarbose to six normal healthy volunteers.Results: There was an early increment in GLP-1 15min after sucrose ingestion. With acarbose, sucrose reached the colon approximately 120min after ingestion, as indicated by an increment in breath hydrogen exhalation (p < 0.0001), and GLP-1 release was prolonged (p < 0.0001). The sucrose-related increments in glucose, insulin, C-peptide, and gastric inhibitory polypeptide (GIP) and the suppression of glucagon were only marginally affected by acarbose administration.Conclusions: GLP-1 release appears to be influenced by indirect mechanisms (early response after sucrose) and by direct luminal contact with lower gut mucosal endocrine cells (late response with acarbose). 相似文献
38.
David S. H. Bell 《Postgraduate medicine》2018,130(4):409-410
Prior to the availability of degludec and regular human insulin inhalation powder in the type 1 diabetic patient glycemic control with subcutaneous insulin injections was difficult to obtain due to nocturnal, pre-prandial and often severe hypoglycemia as well as post-prandial hyperglycemia and hypoglycemia due to ‘stacking’ of insulin. A 62-year-old female with type 1 diabetes for 56 years who could not be controlled with continuous subcutaneous insulin aspart infusion obtained glycemic control without significant hypoglycemia or increased post-prandial glycemic excursions utilizing degludec insulin for basal needs and technosphere before meals and between meals if needed. The availability of degludec and technosphere insulin improved the management of brittle type 1 diabetes. 相似文献
39.
40.